SIGA Technologies, Inc. (SIGA)
USD 5.98
(1.01%)
USD 5.98
(1.01%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 22.04 Million USD | 9.55% |
| 2022 | 35.11 Million USD | 94.73% |
| 2021 | 18.03 Million USD | 22.49% |
| 2020 | 14.72 Million USD | 5.32% |
| 2019 | 13.97 Million USD | 2.26% |
| 2018 | 13.66 Million USD | 3.45% |
| 2017 | 13.21 Million USD | -9.64% |
| 2016 | 14.62 Million USD | 26.16% |
| 2015 | 11.59 Million USD | -14.21% |
| 2014 | 13.51 Million USD | -7.87% |
| 2013 | 14.66 Million USD | 10.32% |
| 2012 | 13.29 Million USD | -69.86% |
| 2011 | 44.1 Million USD | 38.1% |
| 2010 | 31.93 Million USD | 24.32% |
| 2009 | 25.69 Million USD | 52.9% |
| 2008 | 16.8 Million USD | 18.65% |
| 2007 | 14.16 Million USD | 0.67% |
| 2006 | 14.06 Million USD | 27.78% |
| 2005 | 11 Million USD | 2.7% |
| 2004 | 10.71 Million USD | 77.86% |
| 2003 | 6.02 Million USD | 62.46% |
| 2002 | 3.7 Million USD | -16.1% |
| 2001 | 4.42 Million USD | -48.06% |
| 2000 | 8.51 Million USD | 93.46% |
| 1999 | 4.4 Million USD | -25.42% |
| 1998 | 5.9 Million USD | 96.67% |
| 1997 | 3 Million USD | 100.0% |
| 1996 | 1.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 10.92 Million USD | 9.29% |
| 2024 Q2 | 8.41 Million USD | -22.96% |
| 2023 Q2 | 4.42 Million USD | 4.51% |
| 2023 Q3 | 5.99 Million USD | 35.56% |
| 2023 Q4 | 9.99 Million USD | 66.67% |
| 2023 Q1 | 4.23 Million USD | -27.92% |
| 2023 FY | 38.47 Million USD | 9.55% |
| 2022 Q4 | 5.87 Million USD | -70.11% |
| 2022 FY | 35.11 Million USD | 94.73% |
| 2022 Q1 | 3.71 Million USD | -5.33% |
| 2022 Q2 | 5.87 Million USD | 58.28% |
| 2022 Q3 | 19.65 Million USD | 234.62% |
| 2021 Q3 | 4.47 Million USD | -17.07% |
| 2021 Q1 | 4.24 Million USD | 18.43% |
| 2021 Q2 | 5.39 Million USD | 26.89% |
| 2021 Q4 | 3.92 Million USD | -12.33% |
| 2021 FY | 18.03 Million USD | 22.49% |
| 2020 Q1 | 3.35 Million USD | -8.72% |
| 2020 FY | 14.72 Million USD | 5.32% |
| 2020 Q3 | 3.73 Million USD | -7.78% |
| 2020 Q2 | 4.04 Million USD | 20.44% |
| 2020 Q4 | 3.58 Million USD | -3.81% |
| 2019 Q4 | 3.67 Million USD | 9.18% |
| 2019 Q2 | 3.57 Million USD | 6.56% |
| 2019 Q1 | 3.35 Million USD | -16.86% |
| 2019 FY | 13.97 Million USD | 2.26% |
| 2019 Q3 | 3.36 Million USD | -5.72% |
| 2018 Q2 | 3.05 Million USD | -6.6% |
| 2018 FY | 13.66 Million USD | 3.45% |
| 2018 Q1 | 3.27 Million USD | -6.49% |
| 2018 Q3 | 3.3 Million USD | 7.91% |
| 2018 Q4 | 4.03 Million USD | 22.24% |
| 2017 FY | 13.21 Million USD | -9.64% |
| 2017 Q4 | 3.5 Million USD | 4.71% |
| 2017 Q3 | 3.34 Million USD | 2.75% |
| 2017 Q2 | 3.25 Million USD | 4.66% |
| 2017 Q1 | 3.11 Million USD | -33.21% |
| 2016 Q1 | 2.87 Million USD | 1.24% |
| 2016 FY | 14.62 Million USD | 26.16% |
| 2016 Q3 | 3.08 Million USD | -22.44% |
| 2016 Q2 | 3.97 Million USD | 38.33% |
| 2016 Q4 | 4.65 Million USD | 50.93% |
| 2015 FY | 11.59 Million USD | -14.21% |
| 2015 Q3 | 2.51 Million USD | -11.44% |
| 2015 Q1 | 3.42 Million USD | 31.95% |
| 2015 Q2 | 2.84 Million USD | -16.95% |
| 2015 Q4 | 2.84 Million USD | 12.92% |
| 2014 Q2 | 3.02 Million USD | -10.35% |
| 2014 Q1 | 3.37 Million USD | -18.0% |
| 2014 Q3 | 4.61 Million USD | 52.7% |
| 2014 Q4 | 2.59 Million USD | -43.88% |
| 2014 FY | 13.51 Million USD | -7.87% |
| 2013 Q1 | 3.48 Million USD | 133.42% |
| 2013 FY | 14.66 Million USD | 10.32% |
| 2013 Q2 | 3.46 Million USD | -0.65% |
| 2013 Q3 | 3.59 Million USD | 3.69% |
| 2013 Q4 | 4.11 Million USD | 14.47% |
| 2012 Q3 | 7.68 Million USD | -14.92% |
| 2012 Q1 | 7.01 Million USD | -44.89% |
| 2012 FY | 13.29 Million USD | -69.86% |
| 2012 Q4 | -10.44 Million USD | -235.84% |
| 2012 Q2 | 9.03 Million USD | 28.78% |
| 2011 Q4 | 12.72 Million USD | 32.3% |
| 2011 FY | 44.1 Million USD | 38.1% |
| 2011 Q3 | 9.62 Million USD | -29.25% |
| 2011 Q2 | 13.59 Million USD | 66.69% |
| 2011 Q1 | 8.15 Million USD | 11.62% |
| 2010 Q2 | 7.46 Million USD | -7.97% |
| 2010 Q1 | 8.11 Million USD | 5.62% |
| 2010 FY | 31.93 Million USD | 24.32% |
| 2010 Q4 | 7.3 Million USD | -19.18% |
| 2010 Q3 | 9.04 Million USD | 21.07% |
| 2009 Q2 | 6.59 Million USD | 35.61% |
| 2009 FY | 25.69 Million USD | 52.9% |
| 2009 Q4 | 7.68 Million USD | 17.47% |
| 2009 Q3 | 6.54 Million USD | -0.87% |
| 2009 Q1 | 4.86 Million USD | -3.37% |
| 2008 FY | 16.8 Million USD | 18.65% |
| 2008 Q4 | 5.03 Million USD | 26.0% |
| 2008 Q3 | 3.99 Million USD | 5.21% |
| 2008 Q2 | 3.79 Million USD | -4.31% |
| 2008 Q1 | 3.97 Million USD | 3.57% |
| 2007 Q3 | 3.19 Million USD | -7.95% |
| 2007 Q2 | 3.46 Million USD | -5.31% |
| 2007 Q1 | 3.66 Million USD | -15.3% |
| 2007 FY | 14.16 Million USD | 0.67% |
| 2007 Q4 | 3.83 Million USD | 20.02% |
| 2006 Q4 | 4.32 Million USD | 44.45% |
| 2006 Q2 | 4.03 Million USD | 49.05% |
| 2006 Q1 | 2.7 Million USD | -2.02% |
| 2006 FY | 14.06 Million USD | 27.78% |
| 2006 Q3 | 2.99 Million USD | -25.82% |
| 2005 Q2 | 3.48 Million USD | 35.52% |
| 2005 Q3 | 2.18 Million USD | -37.21% |
| 2005 Q4 | 2.76 Million USD | 26.33% |
| 2005 FY | 11 Million USD | 2.7% |
| 2005 Q1 | 2.57 Million USD | -35.22% |
| 2004 Q3 | 1.82 Million USD | -34.73% |
| 2004 Q4 | 3.96 Million USD | 116.96% |
| 2004 FY | 10.71 Million USD | 77.86% |
| 2004 Q1 | 2.11 Million USD | 22.71% |
| 2004 Q2 | 2.8 Million USD | 32.39% |
| 2003 Q3 | 1.75 Million USD | 20.09% |
| 2003 Q1 | 1.09 Million USD | -5.77% |
| 2003 Q4 | 1.72 Million USD | -1.42% |
| 2003 FY | 6.02 Million USD | 62.46% |
| 2003 Q2 | 1.45 Million USD | 33.25% |
| 2002 Q1 | 724.81 Thousand USD | -29.93% |
| 2002 FY | 3.7 Million USD | -16.1% |
| 2002 Q4 | 1.16 Million USD | 60.31% |
| 2002 Q3 | 724.04 Thousand USD | -34.18% |
| 2002 Q2 | 1.09 Million USD | 51.76% |
| 2001 Q1 | 495.96 Thousand USD | -77.38% |
| 2001 FY | 4.42 Million USD | -48.06% |
| 2001 Q4 | 1.03 Million USD | -40.75% |
| 2001 Q3 | 1.74 Million USD | 54.84% |
| 2001 Q2 | 1.12 Million USD | 127.33% |
| 2000 Q2 | 1.61 Million USD | -9.02% |
| 2000 Q1 | 1.77 Million USD | 97.16% |
| 2000 FY | 8.51 Million USD | 93.46% |
| 2000 Q3 | 2.93 Million USD | 81.53% |
| 2000 Q4 | 2.19 Million USD | -25.19% |
| 1999 Q4 | 900 Thousand USD | -18.18% |
| 1999 Q1 | 1.2 Million USD | 0.0% |
| 1999 FY | 4.4 Million USD | -25.42% |
| 1999 Q3 | 1.1 Million USD | 10.0% |
| 1999 Q2 | 1 Million USD | -16.67% |
| 1998 Q4 | 1.2 Million USD | -25.0% |
| 1998 Q1 | 1 Million USD | -9.09% |
| 1998 Q2 | 2.1 Million USD | 110.0% |
| 1998 Q3 | 1.6 Million USD | -23.81% |
| 1998 FY | 5.9 Million USD | 96.67% |
| 1997 FY | 3 Million USD | 100.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | 700 Thousand USD | 0.0% |
| 1997 Q4 | 1.1 Million USD | 57.14% |
| 1996 FY | 1.5 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -167.095% |
| Alpha Teknova, Inc. | 45.85 Million USD | 51.933% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 88.753% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 50.856% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 86.155% |
| Cosmos Health Inc. | 26.18 Million USD | 15.805% |
| Journey Medical Corporation | 54.59 Million USD | 59.624% |
| Embecta Corp. | 528.4 Million USD | 95.828% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 91.893% |
| Dynavax Technologies Corporation | 219.14 Million USD | 89.941% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 96.264% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 93.246% |
| PainReform Ltd. | 9.58 Million USD | -129.998% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -67.954% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -67.954% |
| SCYNEXIS, Inc. | 51.84 Million USD | 57.485% |
| Safety Shot Inc | 12.1 Million USD | -82.028% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -618.204% |
| Procaps Group, S.A. | 199.47 Million USD | 88.95% |
| Theratechnologies Inc. | 72.75 Million USD | 69.703% |
| Harrow Health, Inc. | 89.97 Million USD | 75.5% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -133.358% |
| Biofrontera Inc. | 39.95 Million USD | 44.836% |
| DURECT Corporation | 43.71 Million USD | 49.576% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 95.833% |
| Cronos Group Inc. | 96.7 Million USD | 77.207% |
| OptiNose, Inc. | 85.1 Million USD | 74.098% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 90.504% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 43.7% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 330.551% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 92.983% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -126.528% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 48.785% |
| Radius Health, Inc. | 265.92 Million USD | 91.711% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -59.248% |
| ProPhase Labs, Inc. | 37.85 Million USD | 41.765% |
| Phibro Animal Health Corporation | 260.29 Million USD | 91.532% |
| Procaps Group S.A. | 187.24 Million USD | 88.228% |
| Alvotech | 285.43 Million USD | 92.277% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -124.356% |
| Viatris Inc. | 5.96 Billion USD | 99.631% |
| Rockwell Medical, Inc. | 15.37 Million USD | -43.379% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 63.163% |
| Tilray Brands, Inc. | 251.35 Million USD | 91.23% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 55.049% |
| Shineco, Inc. | 17.94 Million USD | -22.816% |
| PetIQ, Inc. | 192.72 Million USD | 88.562% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -452.299% |
| Incannex Healthcare Limited | 30.05 Million USD | 26.653% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 98.619% |
| Alimera Sciences, Inc. | 62.64 Million USD | 64.811% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -2790.919% |
| Assertio Holdings, Inc. | 368.58 Million USD | 94.02% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -274.526% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -23.778% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -4.129% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -4.757% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 86.638% |
| Hempacco Co., Inc. | 7.59 Million USD | -190.175% |
| Talphera, Inc. | 11.99 Million USD | -83.784% |
| Alvotech | 285.43 Million USD | 92.277% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 84.335% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 93.609% |
| Currenc Group, Inc. | 24 Million USD | 8.162% |
| Kamada Ltd. | 45.42 Million USD | 51.475% |
| Indivior PLC | 911 Million USD | 97.58% |
| Evoke Pharma, Inc. | 12.4 Million USD | -77.628% |
| Flora Growth Corp. | 10.57 Million USD | -108.366% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -4.757% |
| Evolus, Inc. | 189.75 Million USD | 88.384% |
| HUTCHMED (China) Limited | 436.23 Million USD | 94.947% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 85.699% |
| Akanda Corp. | 3.48 Million USD | -532.782% |